Raffaelli B, Neeb L, Reuter U (2019) Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther 19(12):1307–1317
Article
CAS
Google Scholar
Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F et al (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377(22):2123–2132
Article
CAS
Google Scholar
Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Neurology 16(6):425–434
Article
CAS
Google Scholar
Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999–2008
Article
CAS
Google Scholar
Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113–2122
Article
CAS
Google Scholar
Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080–1088
Article
Google Scholar
Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211–e2221
Article
CAS
Google Scholar
Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ (2020) Real-world patient experience with erenumab for the preventive treatment of migraine. Headache 60(9):2014–2025
Article
Google Scholar
Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M et al (2020) Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 21(1):84
Article
CAS
Google Scholar
Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A et al (2020) erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol 11:417
Article
Google Scholar
Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61
Article
CAS
Google Scholar
Kanaan S, Hettie G, Loder E, Burch R (2020) Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia 40(13):1511–1522. https://doi.org/10.1177/03331024211046617
Article
PubMed
Google Scholar
Torres-Ferrús M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (2021) The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol 268(10):3789–3798
Article
Google Scholar
Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20(1):6
Article
Google Scholar
Gantenbein AR, Agosti R, Gobbi C, Flügel D, Schankin CJ, Viceic D et al (2021) Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study. Cephalalgia 41(11–12):1181–1186
Article
Google Scholar
De Matteis E, Affaitati G, Frattale I, Caponnetto V, Pistoia F, Giamberardino MA et al (2021) Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol Sci 42(8):3297–3303
Article
Google Scholar
Raffaelli B, Terhart M, Overeem LH, Mecklenburg J, Neeb L, Steinicke M, et al ( 2021) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia 3331024211046617. https://doi.org/10.1111/ene.15260
Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12(8):963–974
Article
CAS
Google Scholar
Vernieri F, Brunelli N, Messina R, Costa CM, Colombo B, Torelli P et al (2021) Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain 22(1):154
Article
CAS
Google Scholar
Stauffer VL, Wang S, Voulgaropoulos M, Skljarevski V, Kovacik A, Aurora SK (2019) Effect of galcanezumab following treatment cessation in patients with migraine: results from 2 randomized phase 3 trials. Headache 59(6):834–847
Article
Google Scholar
Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Predictors of sustained response and effects of Anti-CGRP antibodies discontinuation and reinitiation in resistant chronic migraine. Eur J Neurol
Post RM, Leverich GS, Altshuler L, Mikalauskas K (1992) Lithium-discontinuation-induced refractoriness: preliminary observations. Am J Psychiatry 149(12):1727–1729
Article
CAS
Google Scholar
Bauer M (1994) Refractoriness induced by lithium discontinuation despite adequate serum lithium levels. Am J Psychiatry 151(10):1522
Article
CAS
Google Scholar
Oostervink F, Nolen WA, Hoenderboom AC, Kupka RW (2000) Risk of inducing resistance upon stopping and restarting lithium after long-term usage. Ned Tijdschr Geneeskd 144(9):401–404
CAS
PubMed
Google Scholar
Appleby B, Wise T, Isaac A (2006) A case of refractoriness to lithium therapy following its discontinuation in a previously responsive patient. Harv Rev Psychiatry 14(6):330–332
Article
Google Scholar
Post RM (2012) Acquired lithium resistance revisited: discontinuation-induced refractoriness versus tolerance. J Affect Disord 140(1):6–13
Article
CAS
Google Scholar
Cohen JM, Ning X, Kessler Y, Rasamoelisolo M, Campos VR, Seminerio MJ et al (2021) Immunogenicity of biologic therapies for migraine: a review of current evidence. J Headache Pain 22(1):3
Article
CAS
Google Scholar
Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 53(4):644–655
Article
Google Scholar
Woolley JM, Bonafede MM, Maiese BA, Lenz RA (2017) Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache 57(9):1399–1408
Article
Google Scholar
Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA et al (2019) Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia 39(11):1455–1464
Article
Google Scholar